NCT06602531View on ClinicalTrials.gov

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

June 13, 2025

Study Completion Date

December 19, 2025

Conditions
Influenza, Human
Interventions
BIOLOGICAL

ARCT-2304

Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.

BIOLOGICAL

Control vaccine younger adults

Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

BIOLOGICAL

Control vaccine older adults

Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

OTHER

Placebo Vaccine

Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

Trial Locations (4)

45212

CTI Clinical Research Center, Cincinnati

80501

Tekton Research, Longmont

91942

Velocity Clinical Research, La Mesa

92408

Velocity Clinical Research, San Bernardino

Sponsors
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Arcturus Therapeutics, Inc.

INDUSTRY

NCT06602531 - Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter